Login / Signup

Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study.

Tanvee VarmaMichelle MelloJoseph S RossCary GrossJennifer E Miller
Published in: BMJ medicine (2023)
This novel approach evaluates trials, products, and sponsors on their fair inclusion of demographic groups in research. For oncology trials, substantial room was noted for improved inclusion of older adults and patients who identify as black or Latinx and transparency around the number of participants identifying as Native Hawaiian, Pacific Islander, American Indian, and Alaska Native. These measures can be used by sponsors, ethics committees, among others, to set and evaluate trial diversity goals to help spur progress toward greater research equity in the US.
Keyphrases
  • clinical trial
  • global health
  • phase ii
  • phase iii
  • study protocol
  • public health
  • palliative care
  • physical activity
  • open label
  • cross sectional
  • big data
  • double blind